文献速递类风湿关节炎

TANK结合激酶1抑制剂在生发中心驱动的胶原诱导性关节炎中的治疗作用

Therapeutic Effects of a TANK-Binding Kinase 1 Inhibitor in Germinal Center-Driven Collagen-Induced Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2018-11-26

该研究在胶原诱导性关节炎(CIA)、抗原诱导性关节炎(AIA)和K/BxN血清转移诱导性关节炎(STIA)小鼠模型中评估TBK-1小分子抑制剂WEHI-112的疗效。WEHI-112选择性消除已建立的抗体依赖性CIA的临床和组织学特征,减少II型胶原特异性IgG1和IgG2b抗体产生,并改变生发中心Tfh细胞表型和B细胞功能,但对AIA和STIA效果甚微。作者认为TBK-1抑制可能对RA及其他生发中心相关自身抗体驱动的炎症性疾病具有治疗潜力。

要点

  • WEHI-112在体外抑制TBK-1依赖的IRF3激活和I型干扰素反应。
  • WEHI-112选择性消除已建立的抗体依赖性CIA的临床和组织学特征,减少II型胶原特异性IgG1和IgG2b抗体。
  • WEHI-112改变CIA中生发中心Tfh细胞表型和B细胞功能,但对AIA和STIA效果甚微。

核心结论

  • TBK-1抑制使用WEHI-112消除了抗体依赖性CIA,因WEHI-112未能抑制非抗体驱动的关节炎症,作者认为该化合物的主要效应最可能是靶向生发中心反应中TBK-1介导的机制,该方法可能对RA和其他生发中心相关自身抗体驱动的炎症性疾病具有治疗潜力。

研究设计与样本

  • 研究使用CIA、AIA和K/BxN STIA模型在C57BL/6和DBA/1小鼠中确定WEHI-112抑制关节炎临床和组织学特征的有效性,并使用免疫组化表征CIA发展中的生发中心群体,使用酶联免疫吸附试验测定WEHI-112处理小鼠与载体处理小鼠的Ig自身抗体水平。

主要发现

  • WEHI-112是一种对TBK-1半选择性但同时对IKKε和JAK2有活性的工具化合物,在体外消除TBK-1依赖的干扰素调节因子3激活并抑制I型干扰素反应。
  • 在体内,WEHI-112处理选择性消除已建立的抗体依赖性CIA的临床和组织学特征,但对非抗体依赖性AIA模型或K/BxN STIA效果甚微。
  • WEHI-112减少致关节炎性II型胶原特异性IgG1和IgG2b抗体产生。
  • WEHI-112改变CIA中生发中心Tfh细胞表型和生发中心B细胞功能。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • WEHI-112是对TBK-1半选择性但对IKKε和JAK2也有活性的工具化合物。
  • WEHI-112对非抗体驱动的AIA和K/BxN STIA效果甚微,作者据此推断其主要效应最可能是靶向生发中心反应中TBK-1介导的机制。
  • 作者在结论中使用「may have therapeutic potential」的限定语气描述该方法对RA和其他生发中心相关自身抗体驱动的炎症性疾病的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The production of class-switched high-affinity autoantibodies derived from organized germinal centers (GCs) is a hallmark of many autoimmune inflammatory diseases, including rheumatoid arthritis (RA). TANK-binding kinase 1 (TBK-1) is a serine/threonine kinase involved in the maturation of GC follicular helper T (Tfh) cells downstream of inducible costimulator signaling. We undertook this study to assess the therapeutic potential of TBK-1 inhibition using the small-molecule inhibitor WEHI-112 in antibody-dependent models of inflammatory arthritis. METHODS: Using the models of collagen-induced arthritis (CIA), antigen-induced arthritis (AIA), and K/BxN serum-transfer-induced arthritis (STIA), we determined the effectiveness of WEHI-112 at inhibiting clinical and histologic features of arthritis in C57BL/6 and DBA/1 mice. We used immunohistochemistry to characterize GC populations during CIA development, and we used enzyme-linked immunosorbent assays to determine levels of Ig autoantibodies in WEHI-112-treated mice compared to vehicle-treated mice. RESULTS: WEHI-112, a tool compound that is semiselective for TBK-1 but that also has activity against IKKε and JAK2, abolished TBK-1-dependent activation of interferon (IFN) regulatory factor 3 and inhibited type I IFN responses in vitro. In vivo, treatment with WEHI-112 selectively abrogated clinical and histologic features of established, antibody-dependent CIA, but had minimal effects on an antibody-independent model of AIA or on K/BxN STIA. In keeping with these findings, WEHI-112 reduced arthritogenic type II collagen-specific IgG1 and IgG2b antibody production. Furthermore, WEHI-112 altered the GC Tfh cell phenotype and GC B cell function in CIA. CONCLUSION: We report that TBK-1 inhibition using WEHI-112 abrogated antibody-dependent CIA. As WEHI-112 failed to inhibit non-antibody-driven joint inflammation, we conclude that the major effect of this compound was most likely the targeting of TBK-1-mediated mechanisms in the GC reaction. This approach may have therapeutic potential in RA and in other GC-associated autoantibody-driven inflammatory diseases.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Louis C, Ngo D, D'Silva DB, et al. Therapeutic Effects of a TANK-Binding Kinase 1 Inhibitor in Germinal Center-Driven Collagen-Induced Arthritis. Arthritis Rheumatol. 2018. PMID: 30009417. doi:10.1002/art.40670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。